RU2753525C2 - Применение соединения карбаминовой кислоты для профилактики или лечения фибромиалгии или функционального синдрома, ассоциированного с фибромиалгией - Google Patents

Применение соединения карбаминовой кислоты для профилактики или лечения фибромиалгии или функционального синдрома, ассоциированного с фибромиалгией Download PDF

Info

Publication number
RU2753525C2
RU2753525C2 RU2018144785A RU2018144785A RU2753525C2 RU 2753525 C2 RU2753525 C2 RU 2753525C2 RU 2018144785 A RU2018144785 A RU 2018144785A RU 2018144785 A RU2018144785 A RU 2018144785A RU 2753525 C2 RU2753525 C2 RU 2753525C2
Authority
RU
Russia
Prior art keywords
fibromyalgia
symptoms
carbamic acid
associated functional
group
Prior art date
Application number
RU2018144785A
Other languages
English (en)
Russian (ru)
Other versions
RU2018144785A (ru
RU2018144785A3 (enExample
Inventor
Мин Дзэ ДЗО
Хан Дзу ЙИ
Сун Гван ХВАНГ
Original Assignee
ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. filed Critical ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД.
Publication of RU2018144785A publication Critical patent/RU2018144785A/ru
Publication of RU2018144785A3 publication Critical patent/RU2018144785A3/ru
Application granted granted Critical
Publication of RU2753525C2 publication Critical patent/RU2753525C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2018144785A 2016-05-19 2017-05-18 Применение соединения карбаминовой кислоты для профилактики или лечения фибромиалгии или функционального синдрома, ассоциированного с фибромиалгией RU2753525C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
KR10-2016-0061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
RU2018144785A RU2018144785A (ru) 2020-06-19
RU2018144785A3 RU2018144785A3 (enExample) 2020-08-11
RU2753525C2 true RU2753525C2 (ru) 2021-08-17

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018144785A RU2753525C2 (ru) 2016-05-19 2017-05-18 Применение соединения карбаминовой кислоты для профилактики или лечения фибромиалгии или функционального синдрома, ассоциированного с фибромиалгией

Country Status (13)

Country Link
US (1) US10849882B2 (enExample)
EP (1) EP3459543B1 (enExample)
JP (1) JP7071287B2 (enExample)
KR (1) KR102489052B1 (enExample)
CN (1) CN109475529B (enExample)
AU (1) AU2017265839B2 (enExample)
BR (1) BR112018073553A2 (enExample)
DK (1) DK3459543T3 (enExample)
ES (1) ES2935596T3 (enExample)
MX (1) MX394245B (enExample)
PL (1) PL3459543T3 (enExample)
RU (1) RU2753525C2 (enExample)
WO (1) WO2017200318A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635941B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
EP3711757B1 (en) * 2017-11-14 2025-05-07 SK Biopharmaceuticals Co., Ltd. Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
CN111432812A (zh) 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
RU2299729C2 (ru) * 2001-07-16 2007-05-27 Орто-Макнейл Фармасьютикал, Инк. Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
EP2445890B1 (en) * 2009-06-22 2015-05-06 SK Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
RU2557533C2 (ru) * 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2299729C2 (ru) * 2001-07-16 2007-05-27 Орто-Макнейл Фармасьютикал, Инк. Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
EP2445890B1 (en) * 2009-06-22 2015-05-06 SK Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
RU2557533C2 (ru) * 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Philip J Wiffen et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews / Cochrane Database Syst Rev; 2013. *
Покровский В.И. Малая медицинская энциклопедия. - М. Большая российская энциклопедия - 1992. - Т.3, 560 с. *
Покровский В.И. Малая медицинская энциклопедия. - М. Большая российская энциклопедия - 1992. - Т.3, 608 с. *
Покровский В.И. Малая медицинская энциклопедия. - М. Большая российская энциклопедия - 1992. - Т.3, 608 с. Покровский В.И. Малая медицинская энциклопедия. - М. Большая российская энциклопедия - 1992. - Т.3, 560 с. Philip J Wiffen et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews / Cochrane Database Syst Rev; 2013. *

Also Published As

Publication number Publication date
ES2935596T3 (es) 2023-03-08
PL3459543T3 (pl) 2023-04-11
EP3459543B1 (en) 2022-12-21
US20190298694A1 (en) 2019-10-03
MX394245B (es) 2025-03-19
BR112018073553A2 (pt) 2019-03-19
CN109475529A (zh) 2019-03-15
RU2018144785A (ru) 2020-06-19
EP3459543A4 (en) 2020-01-15
KR102489052B1 (ko) 2023-01-16
DK3459543T3 (da) 2023-02-13
CA3024286A1 (en) 2017-11-23
WO2017200318A1 (ko) 2017-11-23
MX2018014080A (es) 2019-04-04
US10849882B2 (en) 2020-12-01
JP7071287B2 (ja) 2022-05-18
CN109475529B (zh) 2022-02-22
RU2018144785A3 (enExample) 2020-08-11
AU2017265839B2 (en) 2022-10-27
AU2017265839A1 (en) 2018-12-13
KR20170131242A (ko) 2017-11-29
EP3459543A1 (en) 2019-03-27
JP2019516707A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
EP3459543B1 (en) Carbamate compound for preventing or treating fibromyalgia
US12611395B2 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
EP3711761A1 (en) Use of carbamate compound for reducing or treating developmental disorders including fragile x syndrome, angelman syndrome or rett syndrome
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
IL274428B2 (en) Use of a carbamate compound to prevent, relieve or treat a withdrawal seizure or epilepsy presenting with a withdrawal seizure
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CA3024286C (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
AU2017374459A1 (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
RU2796295C2 (ru) Карбаматное соединение и применение включающей его композиции для профилактики, облегчения или лечения острого стрессового расстройства или посттравматического стрессового расстройства
BR112018073556B1 (pt) Uso de um composto de carbamato